An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK.
Judith ShoreJoel RussellLutz FrankensteinPascal CandolfiMichelle GreenPublished in: Journal of medical economics (2020)
Compared with GDMT, the use of TMVr results in an additional 1.07 QALYs and an increase in costs of £32,267 per patient over a lifetime time horizon. The estimated incremental cost per QALY gained is £30,057 and would therefore be on the threshold of cost-effectiveness at £30,000 per quality adjusted life year. Thus, from a UK reimbursement perspective, in patients with severe functional MR who are at high risk of surgical mortality or deemed inoperable with conventional surgery, TMVr plus medical therapy is likely to represent a cost-effective treatment option compared with GDMT alone. The choice of device (MitraClip or PASCAL) will need to be confirmed once further clinical data are reported.
Keyphrases
- mitral valve
- left atrial
- minimally invasive
- cross sectional
- left ventricular
- cardiovascular events
- coronary artery bypass
- case report
- magnetic resonance
- electronic health record
- early onset
- risk factors
- heart failure
- big data
- quality improvement
- locally advanced
- radiation therapy
- coronary artery disease
- squamous cell carcinoma
- surgical site infection
- magnetic resonance imaging
- replacement therapy
- stem cells
- atrial fibrillation
- machine learning
- combination therapy
- ejection fraction